JP2017514858A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514858A5
JP2017514858A5 JP2016566672A JP2016566672A JP2017514858A5 JP 2017514858 A5 JP2017514858 A5 JP 2017514858A5 JP 2016566672 A JP2016566672 A JP 2016566672A JP 2016566672 A JP2016566672 A JP 2016566672A JP 2017514858 A5 JP2017514858 A5 JP 2017514858A5
Authority
JP
Japan
Prior art keywords
resveratrol
composition
ursolic acid
effective amount
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566672A
Other languages
English (en)
Japanese (ja)
Other versions
JP6716468B2 (ja
JP2017514858A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029224 external-priority patent/WO2015171598A1/en
Publication of JP2017514858A publication Critical patent/JP2017514858A/ja
Publication of JP2017514858A5 publication Critical patent/JP2017514858A5/ja
Application granted granted Critical
Publication of JP6716468B2 publication Critical patent/JP6716468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566672A 2014-05-05 2015-05-05 肥満、糖尿病、または癌を治療するためのウルソル酸および/またはレスベラトロールを含む方法および組成物 Active JP6716468B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988859P 2014-05-05 2014-05-05
US61/988,859 2014-05-05
PCT/US2015/029224 WO2015171598A1 (en) 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020100600A Division JP2020147590A (ja) 2014-05-05 2020-06-10 肥満、糖尿病、または癌を治療するためのウルソル酸および/またはレスベラトロールを含む方法および組成物

Publications (3)

Publication Number Publication Date
JP2017514858A JP2017514858A (ja) 2017-06-08
JP2017514858A5 true JP2017514858A5 (enExample) 2018-06-14
JP6716468B2 JP6716468B2 (ja) 2020-07-01

Family

ID=54392898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016566672A Active JP6716468B2 (ja) 2014-05-05 2015-05-05 肥満、糖尿病、または癌を治療するためのウルソル酸および/またはレスベラトロールを含む方法および組成物
JP2020100600A Pending JP2020147590A (ja) 2014-05-05 2020-06-10 肥満、糖尿病、または癌を治療するためのウルソル酸および/またはレスベラトロールを含む方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020100600A Pending JP2020147590A (ja) 2014-05-05 2020-06-10 肥満、糖尿病、または癌を治療するためのウルソル酸および/またはレスベラトロールを含む方法および組成物

Country Status (6)

Country Link
US (7) US10155003B2 (enExample)
EP (1) EP3139910B1 (enExample)
JP (2) JP6716468B2 (enExample)
AU (2) AU2015256178B2 (enExample)
MY (1) MY181685A (enExample)
WO (1) WO2015171598A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015256178B2 (en) * 2014-05-05 2020-02-27 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
WO2017080958A1 (en) * 2015-11-13 2017-05-18 Unilever Plc Composition for hair follicle growth
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
JP2020526594A (ja) * 2017-07-13 2020-08-31 イースト チャイナ ユニバーシティ オブ サイエンス アンド テクノロジー Pd−1を標的とするサポニン系化合物及びその応用
IL273078B2 (en) * 2017-09-13 2025-06-01 Emmyon Inc Ursolic acid morpholine and diethanolamine salts
EP4433174A4 (en) * 2021-11-18 2025-10-22 Univ Texas COMBINATIONS OF CURCUMIN AND URSOLIC ACID AND THEIR USES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ampk活性化剤
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
JP5339373B2 (ja) * 2006-07-14 2013-11-13 ディーエスエム アイピー アセッツ ビー.ブイ. 組成物および炎症障害の治療、共治療または予防のためのその使用
TWI440456B (zh) * 2007-01-16 2014-06-11 用於治療代謝性症候群之新穎化合物
CN101032564B (zh) * 2007-02-28 2011-03-23 天津津酒集团有限公司 调节血脂养生酒及其制备方法
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
JP5990160B2 (ja) * 2010-04-12 2016-09-07 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーターを使用して肥満を処置する方法
US9393221B2 (en) * 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage
US20140024708A1 (en) 2012-07-17 2014-01-23 Banavara L. Mylari Ursolic acid salts for treating diabetes and obesity
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
AU2015256178B2 (en) * 2014-05-05 2020-02-27 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
KR20230134598A (ko) * 2014-07-29 2023-09-21 센젠 하이타이드 바이오파마슈티컬 리미티드 베르베린 염, 우르소데옥시콜산 염 및 병용물, 이들의 제조 및 응용 방법

Similar Documents

Publication Publication Date Title
JP2017514858A5 (enExample)
JP2018193377A5 (enExample)
JP2015212268A5 (enExample)
JP2015512406A5 (enExample)
JP2011068653A5 (enExample)
JP2010525050A5 (enExample)
JP2016512248A5 (enExample)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2016515628A5 (enExample)
JP2015510916A5 (enExample)
JP2016531885A5 (enExample)
JP2016510326A5 (enExample)
JP2013541583A5 (enExample)
JP2018503644A5 (enExample)
JP2017533220A5 (enExample)
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
JP2016512247A5 (enExample)
JP2016505050A5 (enExample)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2018506533A5 (enExample)
Sturn et al. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients
JP2016522188A5 (enExample)
WO2016003158A3 (ko) DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
JP2018505901A5 (enExample)